A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers

c-Met is a well-characterized oncogene that is associated with poor prognosis in many solid tumor types. While responses to c-Met inhibitors have been observed in clinical trials, activity appears to be limited to those with MET gene amplifications or mutations. We developed a c-Met targeted antibod...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Fujita, Ryo, Blot, Vincent, Wong, Eley, Stewart, Christine, Lieuw, Vincent, Richardson, Robyn, Banah, Ammar, Villicana, Jose, Timmer, Anjuli, Coronella, Julia, Newman, Roland, Gymnopoulos, Marco
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2020
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515515/
https://ncbi.nlm.nih.gov/pubmed/32192391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1737490
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars